Polypharmacology of Approved Anticancer Drugs

被引：25

作者：

Amelio, Ivano ^{[1
]}

Lisitsa, Andrey ^{[2
]}

Knight, Richard A. ^{[1
]}

Melino, Gerry ^{[1
,3
,4
]}

Antonov, Alexey V. ^{[1
,3
]}

机构：

[1] Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England

[2] Russian Acad Med Sci, Inst Biomed Chem, Pogodinskaya St, Moscow, Russia

[3] Inst Cytol, St Petersburg 194064, Russia

[4] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy

来源：

CURRENT DRUG TARGETS | 2017年 / 18卷 / 05期

基金：

英国医学研究理事会;

关键词：

Polypharmacology; tyrosine kinase inhibitors; histone deacetylase inhibitors; DNA topoisomerase inhibitors; tamoxifen; drug targets; rational design of multitarget drugs; TYROSINE KINASE INHIBITORS; HISTONE DEACETYLASE INHIBITORS; CELL-CYCLE; CANCER; SURVIVAL; TARGET; P53; TOOL; PERSPECTIVE; ACTIVATION;

D O I：

10.2174/1389450117666160301095233

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.

引用

页码：534 / 543

页数：10

共 65 条

[1] DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information [J].

Amelio, I. ;

Gostev, M. ;

Knight, R. A. ;

Willis, A. E. ;

Melino, G. ;

Antonov, A. V. .

CELL DEATH & DISEASE, 2014, 5 :e1051-e1051

[2] Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems [J].

Amelio, Ivano ;

Landre, Vivien ;

Knight, Richard A. ;

Lisitsa, Andrey ;

Melino, Gerry ;

Antonov, Alexey V. .

ONCOTARGET, 2015, 6 (12) :9646-9656

[3] Serine and glycine metabolism in cancer [J].

Amelio, Ivano ;

Cutruzzola, Francesca ;

Antonov, Alexey ;

Agostini, Massimiliano ;

Melino, Gerry .

TRENDS IN BIOCHEMICAL SCIENCES, 2014, 39 (04) :191-198

[4] PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome [J].

Antonov, A. V. ;

Krestyaninova, M. ;

Knight, R. A. ;

Rodchenkov, I. ;

Melino, G. ;

Barlev, N. A. .

ONCOGENE, 2014, 33 (13) :1621-1628

[5] MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets [J].

Antonov, A. V. ;

Knight, R. A. ;

Melino, G. ;

Barlev, N. A. ;

Tsvetkov, P. O. .

CELL DEATH AND DIFFERENTIATION, 2013, 20 (02) :367-367

[6] Complex functionality of gene groups identified from high-throughput data [J].

Antonov, Alexey V. ;

Mewes, Hans W. .

JOURNAL OF MOLECULAR BIOLOGY, 2006, 363 (01) :289-296

[7] BioProfiling.de: analytical web portal for high-throughput cell biology [J].

Antonov, Alexey V. .

NUCLEIC ACIDS RESEARCH, 2011, 39 :W323-W327

[8] A systematic approach to infer biological relevance and biases of gene network structures [J].

Antonov, AV ;

Tetko, IV ;

Mewes, HW .

NUCLEIC ACIDS RESEARCH, 2006, 34 (01) :e6

[9] Role of tyrosine kinase inhibitors in cancer therapy [J].

Arora, A ;

Scholar, EM .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979

[10] Tamoxifen non-estrogen receptor mediated molecular targets [J].

Bogush, Tatiana ;

Dudko, Evgeny ;

Bogush, Elena ;

Polotsky, Boris ;

Tjulandin, Sergei ;

Davydov, Mikhail .

ONCOLOGY REVIEWS, 2012, 6 (02) :122-129

← 1 2 3 4 5 6 7 →